PEP
50
-4
SWN
70
3
AIZ
71
-2
TGNA
51
3
AEP
59
-3
PBI
62
2
HBI
59
-2
EXPE
74
2
MCD
63
-4
MRK
53
3
HSIC
56
3
PAYX
53
-4
AN
49
2
CCI
36
-5
EXC
50
-4
BWA
42
-2
CA
36
-4
EA
44
-2
VRTX
56
-4
NRG
57
2
PEP
50
-4
SWN
70
3
AIZ
71
-2
TGNA
51
3
AEP
59
-3
PBI
62
2
HBI
59
-2
EXPE
74
2
MCD
63
-4
MRK
53
3
HSIC
56
3
PAYX
53
-4
AN
49
2
CCI
36
-5
EXC
50
-4
BWA
42
-2
CA
36
-4
EA
44
-2
VRTX
56
-4
NRG
57
2
Financhill
Back

Autolus Therapeutics PLC 10K Form

Sell
32

AUTL
Autolus Therapeutics PLC

Last Price:
3.94
Seasonality Move:
-0.26%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AUTL News And Ratings

See the #1 stock for the next 7 days that we like better than AUTL

AUTL Financial Statistics

Sales & Book Value

Annual Sales: $1.7M
Cash Flow: $-51.92M
Price / Cash Flow: 0
Annual Sales: $1.98
Price / Book: 1.95

Profitability

EPS (TTM): -1.17000
Net Income (TTM): $-233.98M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Autolus Therapeutics PLC Earnings Forecast

Key Autolus Therapeutics PLC Financial Ratios

  • The Research & Development expenses have been 7,684.39% of Revenue.
  • The Interest Expense is -21.63% of Operating Income.
  • The Net Earning history of AUTL is -12,272.26% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 5 years.

Autolus Therapeutics PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AUTL
CUSIP: 05280R
Website: autolus.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AUTL Technical Analysis vs Fundamental Analysis

Sell
32
Autolus Therapeutics PLC (AUTL) is a Sell

Is Autolus Therapeutics PLC a Buy or a Sell?